Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enanta Pharmaceuticals, Inc. (ENTA) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered securities documents. As a Nasdaq Global Select Market issuer, Enanta uses these filings to report material events, financial results, capital markets transactions, and key clinical and corporate developments related to its small molecule virology and immunology programs.
Investors can review Form 8-K filings in which Enanta reports quarterly and annual financial results, including royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET and commentary on cash, cash equivalents and marketable securities. Other 8-Ks describe public offerings of common stock, such as underwriting agreements, expected net proceeds, and closing conditions for upsized offerings used to fund clinical trials, research, and general corporate purposes.
Filings also capture clinical and R&D milestones, for example the disclosure of positive topline data from the Phase 2b high-risk adult RSV study of zelicapavir, including symptom resolution, virology endpoints, and safety outcomes. Regulation FD 8-Ks may furnish slide presentations or press releases detailing these results. Additional 8-Ks document corporate governance and management changes, such as interim appointments to principal financial officer and principal accounting officer roles.
Enanta’s SEC reports further reference legal and intellectual property matters, including its announcement of a patent infringement suit in the Unified Patent Court of the European Union regarding European Patent No. EP 4 051 265 and Pfizer’s Paxlovid. Through Stock Titan, users can access these filings as they are posted to EDGAR, while AI-powered summaries help explain the implications of complex documents like 8-Ks, registration statements, and related exhibits. This allows readers to quickly understand how financings, clinical data disclosures, and legal actions may relate to Enanta’s RSV and immunology pipelines and its royalty-funded business model.
Enanta Pharmaceuticals reported a narrower net loss for its fiscal first quarter ended December 31, 2025 while advancing its RSV and immunology pipelines. Revenue rose to $18.6 million from $17.0 million, driven by higher royalties on AbbVie’s MAVYRET®/MAVIRET® hepatitis C treatment.
Research and development expense fell to $20.9 million from $27.7 million and general and administrative expense declined to $9.0 million from $12.8 million, reflecting lower clinical, stock-based compensation and legal costs. Net loss improved to $11.9 million, or $0.42 per diluted share, from $22.3 million, or $1.05 per diluted share.
Enanta ended the quarter with $241.9 million in cash, cash equivalents and marketable securities and expects this, plus its retained portion of future royalty revenue, to fund operations into fiscal 2029. The company is conducting Phase 3 enabling work for RSV candidate zelicapavir, progressing RSV drug EDP-323, and advancing three immunology programs, including KIT inhibitor EDP-978 and STAT6 inhibitor EPS-3903, with multiple planned IND filings and data milestones in 2026.
Enanta Pharmaceuticals Inc. received an amended ownership report from Farallon-affiliated investors. The Schedule 13G/A (Amendment No. 7) shows multiple Farallon funds and related entities collectively reporting beneficial ownership positions in Enanta’s common stock.
The largest reported position is by Farallon Partners, L.L.C., which is listed with 2,640,779 Shares, representing 9.1% of the class. Several Farallon Individual Reporting Persons, including Joshua J. Dapice and others, are each reported as beneficial owners of 2,816,862 Shares, or 9.8% of the class, through their roles over the Farallon funds.
The amendment discloses governance changes in the Farallon General Partner structure. Effective January 1, 2026, Avner A. Husen became a member/manager of the relevant general partners and may be deemed a beneficial owner. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased those roles and may no longer be deemed beneficial owners. The group certifies the holdings are not for the purpose of changing or influencing control, and the filing is made under Rule 13d-1(c).
Enanta Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on March 11, 2026. Stockholders of record as of January 16, 2026, when 29,018,522 common shares were outstanding, can vote online, by phone, mail or during the webcast.
Two Class I directors, Bruce L.A. Carter and CEO Jay R. Luly, are nominated for new three-year terms. A key item is an amendment to the 2019 Equity Incentive Plan to add 1,600,000 shares to the share reserve, equal to 5.5% of common shares outstanding as of December 31, 2025. The board explains that equity awards are broadly granted, central to pay, and that Enanta’s three-year average net burn rate was 4.1% through fiscal 2025.
Stockholders are also asked to approve, on an advisory basis, 2025 compensation for named executive officers and to ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026. The proxy outlines board independence, committee structure and significant institutional ownership positions, including several holders above 5%.
Enanta Pharmaceuticals, Inc. received an amended Schedule 13G/A showing institutional investors led by Millennium entities holding a small, passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 665,953 shares, representing 2.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 670,428 shares, also equal to 2.3% of the class, as of the event date December 31, 2025.
The filing states that these securities are not held for the purpose of changing or influencing control of Enanta and are reported on a Schedule 13G/A, which is used for passive ownership. The filing also confirms that the reporting persons each own 5% or less of Enanta’s outstanding common stock. A joint filing agreement among the reporting entities and Israel A. Englander is attached as an exhibit.
Enanta Pharmaceuticals’ chief business officer reported a small share withholding related to previously granted equity. On 12/01/2025, 498 shares of Enanta common stock were forfeited at $14.12 per share to cover withholding taxes from the settlement of a portion of a restricted stock unit award granted on November 19, 2021.
After this tax-related share forfeiture, the officer beneficially owns 39,723 shares of Enanta common stock in direct ownership. The transaction reflects routine equity compensation and tax settlement activity for a senior executive.
Enanta Pharmaceuticals (ENTA) reported an equity compensation grant to its Vice President, Finance, who is its principal financial officer. On 11/25/2025, the officer received 6,463 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing direct beneficial ownership of common stock to 17,375 shares following the transaction. The RSUs vest 25% on December 1, 2026, then in substantially equal annual installments over the next three anniversaries.
The filing also reports a grant of a stock option for 12,925 shares of common stock at an exercise price of $13.66 per share, expiring on 11/25/2035. This option becomes exercisable in substantially equal quarterly installments over four years from the grant date of November 25, 2025, resulting in 12,925 derivative securities beneficially owned after the transaction, all held directly.
Enanta Pharmaceuticals (ENTA) reported a new equity award to an executive officer. The filing shows the Chief Product Strategy Officer received a stock option to buy 100,000 shares of Enanta common stock at an exercise price of $13.66 per share, granted on November 25, 2025.
The option becomes exercisable in substantially equal quarterly installments over four years from the grant date, with any fractional shares carried forward to the next period, and expires on November 25, 2035. Following this grant, the reporting person beneficially owns 100,000 derivative securities directly in the form of this stock option.
Enanta Pharmaceuticals Inc. (ENTA) reported a stock option grant to its Chief Scientific Officer on a Form 4. On November 25, 2025, the officer received a stock option to purchase 110,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.
The option covers 110,000 underlying shares of common stock and is held directly. It becomes exercisable, subject to continued employment, in substantially equal quarterly installments over four years from the grant date, with fractional shares cumulated and becoming exercisable once a whole share equivalent is reached.
Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director. On November 25, 2025, the insider received a stock option to purchase 310,000 shares of Enanta common stock at an exercise price of
The option is scheduled to become exercisable in substantially equal quarterly installments over four years from the grant date, subject to the optionholder’s continued employment. Following this grant, the reporting person beneficially owns 310,000 derivative securities directly in the form of this stock option.